Cargando…
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations a...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694976/ https://www.ncbi.nlm.nih.gov/pubmed/33171712 http://dx.doi.org/10.3390/ph13110371 |
_version_ | 1783615094174777344 |
---|---|
author | Hochmair, Maximilian J. Fabikan, Hannah Illini, Oliver Weinlinger, Christoph Setinek, Ulrike Krenbek, Dagmar Prosch, Helmut Rauter, Markus Schumacher, Michael Wöll, Ewald Wass, Romana Brehm, Elmar Absenger, Gudrun Bundalo, Tatjana Errhalt, Peter Urban, Matthias Valipour, Arschang |
author_facet | Hochmair, Maximilian J. Fabikan, Hannah Illini, Oliver Weinlinger, Christoph Setinek, Ulrike Krenbek, Dagmar Prosch, Helmut Rauter, Markus Schumacher, Michael Wöll, Ewald Wass, Romana Brehm, Elmar Absenger, Gudrun Bundalo, Tatjana Errhalt, Peter Urban, Matthias Valipour, Arschang |
author_sort | Hochmair, Maximilian J. |
collection | PubMed |
description | In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations and thus offers potential benefit in later lines, although real-world data are lacking. This multicenter study retrospectively investigated later-line, real-world use of lorlatinib in patients with advanced ALK- or ROS1-positive lung cancer. Fifty-one patients registered in a compassionate use program in Austria, who received second- or later-line lorlatinib between January 2016 and May 2020, were included in this retrospective real-world data analysis. Median follow-up was 25.3 months. Median time of lorlatinib treatment was 4.4 months for ALK-positive and 12.2 months for ROS-positive patients. ALK-positive patients showed a response rate of 43.2%, while 85.7% percent of the ROS1-positive patients were considered responders. Median overall survival from lorlatinib initiation was 10.2 and 20.0 months for the ALK- and ROS1-positive groups, respectively. In the ALK-positive group, lorlatinib proved efficacy after both brigatinib and alectinib. Lorlatinib treatment was well tolerated. Later-line lorlatinib treatment can induce sustained responses in patients with advanced ALK- and ROS1-positive lung cancer. |
format | Online Article Text |
id | pubmed-7694976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76949762020-11-28 Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis Hochmair, Maximilian J. Fabikan, Hannah Illini, Oliver Weinlinger, Christoph Setinek, Ulrike Krenbek, Dagmar Prosch, Helmut Rauter, Markus Schumacher, Michael Wöll, Ewald Wass, Romana Brehm, Elmar Absenger, Gudrun Bundalo, Tatjana Errhalt, Peter Urban, Matthias Valipour, Arschang Pharmaceuticals (Basel) Article In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations and thus offers potential benefit in later lines, although real-world data are lacking. This multicenter study retrospectively investigated later-line, real-world use of lorlatinib in patients with advanced ALK- or ROS1-positive lung cancer. Fifty-one patients registered in a compassionate use program in Austria, who received second- or later-line lorlatinib between January 2016 and May 2020, were included in this retrospective real-world data analysis. Median follow-up was 25.3 months. Median time of lorlatinib treatment was 4.4 months for ALK-positive and 12.2 months for ROS-positive patients. ALK-positive patients showed a response rate of 43.2%, while 85.7% percent of the ROS1-positive patients were considered responders. Median overall survival from lorlatinib initiation was 10.2 and 20.0 months for the ALK- and ROS1-positive groups, respectively. In the ALK-positive group, lorlatinib proved efficacy after both brigatinib and alectinib. Lorlatinib treatment was well tolerated. Later-line lorlatinib treatment can induce sustained responses in patients with advanced ALK- and ROS1-positive lung cancer. MDPI 2020-11-07 /pmc/articles/PMC7694976/ /pubmed/33171712 http://dx.doi.org/10.3390/ph13110371 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hochmair, Maximilian J. Fabikan, Hannah Illini, Oliver Weinlinger, Christoph Setinek, Ulrike Krenbek, Dagmar Prosch, Helmut Rauter, Markus Schumacher, Michael Wöll, Ewald Wass, Romana Brehm, Elmar Absenger, Gudrun Bundalo, Tatjana Errhalt, Peter Urban, Matthias Valipour, Arschang Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
title | Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
title_full | Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
title_fullStr | Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
title_full_unstemmed | Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
title_short | Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis |
title_sort | later-line treatment with lorlatinib in alk- and ros1-rearrangement-positive nsclc: a retrospective, multicenter analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694976/ https://www.ncbi.nlm.nih.gov/pubmed/33171712 http://dx.doi.org/10.3390/ph13110371 |
work_keys_str_mv | AT hochmairmaximilianj laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT fabikanhannah laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT illinioliver laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT weinlingerchristoph laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT setinekulrike laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT krenbekdagmar laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT proschhelmut laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT rautermarkus laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT schumachermichael laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT wollewald laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT wassromana laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT brehmelmar laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT absengergudrun laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT bundalotatjana laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT errhaltpeter laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT urbanmatthias laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis AT valipourarschang laterlinetreatmentwithlorlatinibinalkandros1rearrangementpositivensclcaretrospectivemulticenteranalysis |